Genomic Analysis of Emerging Florfenicol-Resistant Campylobacter coli Isolated from the Intestinal Cecal Contents of Cattle in the United States

Abstract

ObjectiveGenomic analyses were performed on florfenicol resistant (FFNR) Campylobacter coli (C. coli) isolated from cattle and the cfr(C) gene-associated multi-drug resistance (MDR) plasmid was characterized.\n\nMethodsSixteen FFNR C. coli isolates recovered between 2013-2018 from beef cattle were sequenced using MiSeq. Genomes and plasmids were closed for three of the isolates using the PacBio(R) system. Single nucleotide polymorphisms (SNPs) across the genome and the structures of MDR plasmids were investigated. Conjugation experiments were performed to determine the transferability of cfr(C) associated MDR plasmids. The spectrum of resistance encoded by the cfr(C) gene was further investigated by agar dilution antimicrobial susceptibility testing.\n\nResultsAll 16 FFNR isolates were MDR and exhibited co-resistance to ciprofloxacin, nalidixic acid, clindamycin and tetracycline. All isolates shared the same resistance genotype, carrying aph(3)-III, hph, {triangleup}aadE (truncated), blaOXA-61, cfr(C), and tet(O) genes plus a mutation of GyrA T86I. The cfr(C), aph(3)-III, hph {triangleup}aadE, and tet(O) genes were co-located on transferable MDR plasmids with size 48-50 kb. These plasmids showed high sequence homology with the pTet plasmid, and carried several Campylobacter virulence genes, including virB2, virB4, virB5, VirB6, virB7, virB8, virb9, virB10, virB11 and virD4. The cfr(C) gene conferred resistance to florfenicol (8-32 {micro}g/ml), clindamycin (512-1,024 {micro}g/ml), linezolid (128-512 {micro}g/ml), and tiamulin (1,024 {micro}g/ml). Phylogenetic analysis showed SNP differences ranging from 11-2,248 among the 16 isolates.\n\nConclusionsThe results showed that the cfr(C) gene located in the conjugative pTet MDR/virulence plasmid is present in diverse strains, where it confers high levels of resistance to several antimicrobials, including linezolid, a critical drug for treating Gram positive bacterial infections in humans. This study highlights the power of genomic antimicrobial resistance surveillance to uncover the intricacies of transmissible co-resistance and provides information that is needed for accurate risk assessment and mitigation strategies.